Your trusted source for investing success

Tag: fcx

Fibrocell Announces FDA Fast Track Designation of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa

Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the U. S. Food and Drug Administration (FDA) has granted Fast Track designation to FCX-007, the Company’s clinical-stage candidate for the treatment of Recessive Dystrophic Epidermolysis Bullosa

Copper Trends: A Review of 2016

Copper Trends: A Review of 2016

Copper is at a turning point, and if the copper mining juniors are any indication – it will be a busy year ahead. Here we recap 2016, and look at companies to watch in 2017.

Fibrocell Announces Leadership Changes

Fibrocell Science today announced that John Maslowski has been appointed Chief Executive Officer (CEO) and Douglas Swirsky has been appointed Chairman of the Company’s Board of Directors, succeeding David Pernock effective immediately.

Enter Your Log In Credentials
×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network